ADCendo ApS
- Country
- 🇩🇰Denmark
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.adcendo.dk
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
- Conditions
- Metastatic Soft Tissue SarcomaUnresectable Soft Tissue Sarcoma
- Interventions
- Biological: Antibody-drug conjugate (ADC)
- First Posted Date
- 2025-01-29
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Adcendo ApS
- Target Recruit Count
- 270
- Registration Number
- NCT06797999
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York City, New York, United States
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-10-16
- Lead Sponsor
- Adcendo ApS
- Target Recruit Count
- 210
- Registration Number
- NCT06597721
- Locations
- 🇺🇸
START San Antonio, San Antonio, Texas, United States
🇺🇸Highlands Oncology Group, Rogers, Arkansas, United States
🇺🇸Yale University Cancer Center, New Haven, Connecticut, United States
News
FDA Grants Fast Track Designation to Adcendo's ADCE-D01 for Soft Tissue Sarcoma Treatment
The FDA has granted Fast Track designation to ADCE-D01, a first-in-class antibody-drug conjugate developed by Adcendo ApS for treating soft tissue sarcoma.